Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IDP-121 + Topotecan |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IDP-121 | IDP 121|IDP121 | c-MYC Inhibitor 12 | IDP-121 is peptide that targets Myc, potentially leading to decreased tumor cell viability and inhibition of tumor growth (Cancer Res (2021) 81 (13_Supplement): 1291). | |
| Topotecan | Hycamtin | Topotecan Hcl | Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07864207 | Phase Ib/II | IDP-121 IDP-121 + Topotecan | Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic) (MYCrocytic) | Recruiting | ESP | 0 |